articleTop 1% cited

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

The Lancet Oncology · 2017 · Vol. 18(11) · pp. 1483–1492

Arjun Vasant Balar✉(NYU Langone Health)Daniel Castellano(Hospital Universitario 12 De Octubre)Peter H. O’Donnell(University of Chicago Medical Center)Petros Grivas(Cleveland Clinic)Jacqueline Vuky(Oregon Health & Science University)Thomas Powles(Queen Mary University of London)Elizabeth R. Plimack(Fox Chase Cancer Center)Noah M. Hahn(Sidney Kimmel Comprehensive Cancer Center)Ronald de Wit(Erasmus MC Cancer Institute)Lei Pang(Merck & Co., Inc., Rahway, NJ, USA (United States))Mary J. Savage(Merck & Co., Inc., Rahway, NJ, USA (United States))Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States))Stephen J. O’Keefe(Merck & Co., Inc., Rahway, NJ, USA (United States))Dean F. Bajorin(Memorial Sloan Kettering Cancer Center)Joaquim Bellmunt(Dana-Farber Cancer Institute)

View via DOI Publisher page

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary and Genital Oncology StudiesMedicinePembrolizumabClinical endpointInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyMetastatic Urothelial CarcinomaPhases of clinical researchUrothelial cancerPopulation

MeSH terms

AgedAged, 80 and overCarcinoma, Transitional CellCisplatinDose-Response Relationship, DrugDrug Administration ScheduleHumansInfusions, IntravenousMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisProspective StudiesUrologic NeoplasmsSurvival Analysis